IN8BIO Business Summary

IN8bio, Inc. (INAB) is a clinical-stage biopharmaceutical company specializing in the development of gamma-delta (γδ) T cell therapies for oncology and autoimmune diseases. The company operates as a pre-revenue entity, deriving its valuation from the advancement of its proprietary DeltEx™ platform and Drug Resistant Immunotherapy (DRI) technology, which engineers γδ T cells to survive and function alongside standard-of-care chemotherapy. Its primary business segments are divided into hematologic malignancies, targeting high-risk acute myeloid leukemia (AML) with its INB-100 program, and solid tumors, specifically glioblastoma (GBM) via the INB-400 and INB-200 candidates. Recently, the company expanded into the autoimmune sector with INB-619, a first-in-class pan-γδ T cell engager. IN8bio competes directly with other immunotherapy-focused firms such as RenovoRx (RNXT), NextCure (NXTC), Atara Biotherapeutics (ATRA), and Generation Bio (GBIO), distinguishing itself through its unique focus on the innate-adaptive bridge provided by γδ T cells rather than traditional alpha-beta T cell approaches. The leadership team is anchored by Co-Founder and CEO William Ho, who brings over 24 years of experience across biotechnology and healthcare finance, including tenures at New Leaf Venture Partners and Bank of America. He is joined by Co-Founder and Chief Scientific Officer Dr. Lawrence S. Lamb, a world-renowned pioneer in γδ T cell research whose seminal work at the University of Alabama at Birmingham established the clinical link between these cells and cancer survival. In February 2026, the company strengthened its executive tier by promoting Dr. Kate Rochlin to President and Chief Operating Officer, leveraging her 17-year pedigree in biotech operations and business development from firms like Curadigm. Financial oversight is managed by CFO Patrick McCall, a CPA with extensive experience in life sciences fiscal management. IN8bio is backed by prominent institutional investors, including Stonepine Capital Management, Franklin Resources, and Alyeska Investment Group, and its board of directors includes industry veterans such as Corinne Epperly.